Lactate transporters as therapeutic targets in cancer and inflammatory disease

Research output: Contribution to journalReview articlepeer-review

Standard

Lactate transporters as therapeutic targets in cancer and inflammatory disease. / Pucino, Valentina; Cucchi, Danilo; Mauro, Claudio.

In: Expert Opinion on Therapeutic Targets, 08.2018.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{64774118b3754435a50f34e3b8e4d0bc,
title = "Lactate transporters as therapeutic targets in cancer and inflammatory disease",
abstract = "Introduction: Inflammation is associated with the accumulation of lactate at sites of tumour growth and inflammation. Lactate initiates tissue responses contributing to disease. We discuss the potential of targeting lactate transporters in the treatment of cancer and inflammatory conditions. Areas covered: Lactate is the product of glycolysis, which is considered to be a waste metabolite and a fuel for oxidative cells. It is also an active signalling molecule with immunomodulatory and angiogenic properties. They are the consequence of lactate binding to membrane receptor(s) or being transported through specific carrier-mediated transporters across the cellular membrane. Carriers are distinct in proton-linked monocarboxylate transporters (MCTs) and Na+-coupled electrogenic transporters (SMTCs), expressed by several tissues including immune system, endothelium and epithelium. Several tumours and inflammatory sites (i.e., arthritic synovium, atherosclerotic plaque) show accumulation of lactate and altered expression of its transporters, thus suggesting a role of this metabolite in cancer and inflammatory disorders. We review the most recent evidence on lactate biology, focusing on transporter expression and function in health and disease. Expert opinion: Lactate-initiated signalling is gaining attention for its implications in cancer and inflammation. This review deals with the therapeutic potential of targeting lactate transporters and drugs that are already in clinical use for cancer and discusses the opportunity to develop new therapeutics for inflammatory disease based on recent findings.",
keywords = "lactate, lactate transporter, inflammation, metabolism, immunity, cancer",
author = "Valentina Pucino and Danilo Cucchi and Claudio Mauro",
year = "2018",
month = aug,
doi = "10.1080/14728222.2018.1511706",
language = "English",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Taylor & Francis",

}

RIS

TY - JOUR

T1 - Lactate transporters as therapeutic targets in cancer and inflammatory disease

AU - Pucino, Valentina

AU - Cucchi, Danilo

AU - Mauro, Claudio

PY - 2018/8

Y1 - 2018/8

N2 - Introduction: Inflammation is associated with the accumulation of lactate at sites of tumour growth and inflammation. Lactate initiates tissue responses contributing to disease. We discuss the potential of targeting lactate transporters in the treatment of cancer and inflammatory conditions. Areas covered: Lactate is the product of glycolysis, which is considered to be a waste metabolite and a fuel for oxidative cells. It is also an active signalling molecule with immunomodulatory and angiogenic properties. They are the consequence of lactate binding to membrane receptor(s) or being transported through specific carrier-mediated transporters across the cellular membrane. Carriers are distinct in proton-linked monocarboxylate transporters (MCTs) and Na+-coupled electrogenic transporters (SMTCs), expressed by several tissues including immune system, endothelium and epithelium. Several tumours and inflammatory sites (i.e., arthritic synovium, atherosclerotic plaque) show accumulation of lactate and altered expression of its transporters, thus suggesting a role of this metabolite in cancer and inflammatory disorders. We review the most recent evidence on lactate biology, focusing on transporter expression and function in health and disease. Expert opinion: Lactate-initiated signalling is gaining attention for its implications in cancer and inflammation. This review deals with the therapeutic potential of targeting lactate transporters and drugs that are already in clinical use for cancer and discusses the opportunity to develop new therapeutics for inflammatory disease based on recent findings.

AB - Introduction: Inflammation is associated with the accumulation of lactate at sites of tumour growth and inflammation. Lactate initiates tissue responses contributing to disease. We discuss the potential of targeting lactate transporters in the treatment of cancer and inflammatory conditions. Areas covered: Lactate is the product of glycolysis, which is considered to be a waste metabolite and a fuel for oxidative cells. It is also an active signalling molecule with immunomodulatory and angiogenic properties. They are the consequence of lactate binding to membrane receptor(s) or being transported through specific carrier-mediated transporters across the cellular membrane. Carriers are distinct in proton-linked monocarboxylate transporters (MCTs) and Na+-coupled electrogenic transporters (SMTCs), expressed by several tissues including immune system, endothelium and epithelium. Several tumours and inflammatory sites (i.e., arthritic synovium, atherosclerotic plaque) show accumulation of lactate and altered expression of its transporters, thus suggesting a role of this metabolite in cancer and inflammatory disorders. We review the most recent evidence on lactate biology, focusing on transporter expression and function in health and disease. Expert opinion: Lactate-initiated signalling is gaining attention for its implications in cancer and inflammation. This review deals with the therapeutic potential of targeting lactate transporters and drugs that are already in clinical use for cancer and discusses the opportunity to develop new therapeutics for inflammatory disease based on recent findings.

KW - lactate

KW - lactate transporter

KW - inflammation

KW - metabolism

KW - immunity

KW - cancer

UR - http://europepmc.org/abstract/med/30106309

U2 - 10.1080/14728222.2018.1511706

DO - 10.1080/14728222.2018.1511706

M3 - Review article

C2 - 30106309

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

ER -